- **Phase III Progress**: On track for North American enrollment completion next month, with top-line results expected mid-2026.
- **Dual Mechanism Innovation**: Bemnifosbuvir inhibits both viral replication and assembly secretion, offering superior potency and resistance to NS5A mutations.
- **HEV Pipeline Expansion**: Two new candidates with 20x potency over ribavirin target unmet needs in immunocompromised patients.
- **Financial Strength**: $329.3 million cash runway through 2027, supporting Phase III execution and new program launches.
- **Strategic Differentiation**: No interaction with acid reducers, addressing 35% of HCV patients who use such medications.

**【Management Opening Remarks】**
- Jonae Barnes provided an overview of the call, highlighting the company's Phase III program progress, financial results, and new research findings. She emphasized the strong cash position of $329.3 million, providing runway through 2027.

**【CEO Summary Section】**
- Jean-Pierre Sommadossi highlighted the Phase III program for HCV treatment, with enrollment on track for completion in North America next month and top-line results expected mid-2026. He announced new dual mechanism of action data for bemnifosbuvir, showing inhibition of viral assembly and secretion, and the expansion of the pipeline to include two new HEV candidates.

**【CDO Financial Commentary】**
- Janet Hammond detailed the Phase III program's design, comparing the regimen to Epclusa, and highlighted data showing no interaction with proton pump inhibitors, a key differentiator. She also mentioned a virtual panel discussion on HCV treatment needs.

**【CMO Financial Commentary】**
- Maria Horga provided updates on the global Phase III trials (C-BEYOND and C-FORWARD), emphasizing the regimen's convenience and efficacy. Enrollment is expected to complete mid-2026, with results by late 2026.

**【CEO Dual Mechanism Update】**
- Jean-Pierre presented in vitro data showing bemnifosbuvir's dual mechanism of action, blocking both intracellular replication and viral assembly secretion, which may explain its higher potency compared to sofosbuvir.

**【CCO New Pipeline Expansion】**
- John Vavricka discussed the unmet need for HEV treatments in immunocompromised patients, presenting two new candidates with 20x higher potency than ribavirin. IND-enabling studies are ongoing.

**【CFO Financial Update】**
- Andrea Corcoran reported Q3 2025 financials: R&D expenses increased due to Phase III spending, G&A decreased due to lower stock-based compensation. The company completed a $25 million share repurchase program and maintains a strong cash position.

**【Q&A Highlights】**
- **Differentiation from Epclusa**: Janet Hammond emphasized the regimen's lack of interaction with acid reducers, a significant advantage over Epclusa. 
- **Genotype 3 Efficacy**: Jean-Pierre noted faster time to undetectable in genotype 3 patients, potentially due to the dual mechanism and historical in vitro potency against genotype 3.


Atea Pharmaceuticals, Inc. (AVIR) Q3 2025 Earnings Call Transcript

Revenue

Sales and Services Revenue

Financing Services Revenue

Other Revenue

Cost of Revenue

Cost of Goods and Services

Cost of Financing Services

Other Cost

Gross Profit

Other Operating Income

Operating Expenses

Selling, General and Administrative Expenses

Selling and Marketing Expenses

General and Administrative Expenses

Research and Development Expenses

Loss on Bad Debts

Loss on Impairment of Other Assets

Loss on Disposal of Assets

Other Operating Expenses

Operating Income

Non-Operating Income (Loss)

Income (Loss) from Affiliates

Income (Loss) from Associates

Income (Loss) from Joint ventures

Gain (Loss) on Other Investment

Gain (Loss) on Change in Fair Value

Gain (Loss) on Foreign Currency Exchange

Other Non-Operating Income (Loss)

Net Interest Expense

Interest Expense

Interest Income

Pretax Income From Continuing Operations

Income Tax Expense

Current Income Tax

Deferred Income Tax

Income Tax Adjustments

Net Income from Continuing Operations

Income from Discontinued Operations

Other Items Before Net Income

Net Income

Net Income Attributable to Minority Interests

Net Income Attributable to Owners of the Company

Preferred Stock Dividends

Other Adjustments

Net Income Attributable to Common Stockholders

Other Comprehensive Income

Total Comprehensive Income

Total Comprehensive Income Attributable to Minority Interests

Total Comprehensive Income Attributable to Owners of the Company

Basic EPS

Basic EPS from Continuing Operations

Basic EPS from Discontinued Operations

Diluted EPS

Diluted EPS from Continuing Operations

Diluted EPS from Discontinued Operations

AVIR

AVIR fundamentals

You can ask Aime